Letters to the Editor

To the Editors of the Journal of Alzheimer's Disease,

Dr. Yang and colleagues published a manuscript titled "Rapid Cognitive Assessment: Accuracy and Discriminant Validity of Mini-Cog and Process-Based Clock Drawing" in the January issue of the Journal of Alzheimer's Disease [1]. The authors concluded that the Mini-Cog3 was an effective screening method for the rapid and accurate detection of cognitive dysfunction in patients with mild cognitive impairment and Alzheimer's disease.

We are writing regarding the recently published article, "Explore the Role of Frailty as a Contributor to the Association Between AT(N) Profiles and Cognition in Alzheimer’s Disease," by Han et al. [1]. The study addresses a critical and underexplored dimension of Alzheimer’s disease (AD) pathology, presenting frailty as a potential moderator of the relationship between AT(N) profiles and cognitive impairment.

I want to comment on the paper by Costa and colleagues on a Bayesian re-analysis of the Lecanemab phase 3 Clarity trial [1]. Costa and colleagues had already very meritoriously presented a Bayesian meta-analysis of the Aducanumab Phase 3 trials [2]. They contribute to a growing field of research that adopts Bayesian approaches to overcome limitations of frequentist p-value based statistical inference [3].

I congratulate the authors of the study “A Mediterranean Diet and Walking Intervention to Reduce Cognitive Decline and Dementia Risk in Independently Living Older Australians: The MedWalk Randomized Controlled Trial Experimental Protocol, Including COVID-19 Related Modifications and Baseline Characteristics” published in the Journal of Alzheimer's Disease [1], for developing and contributing to the field of non-pharmacological interventions and lifestyle changes to reduce the risk of dementia and Alzheimer's disease in older adults.